AR093318A1 - Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc) - Google Patents

Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc)

Info

Publication number
AR093318A1
AR093318A1 ARP130103990A ARP130103990A AR093318A1 AR 093318 A1 AR093318 A1 AR 093318A1 AR P130103990 A ARP130103990 A AR P130103990A AR P130103990 A ARP130103990 A AR P130103990A AR 093318 A1 AR093318 A1 AR 093318A1
Authority
AR
Argentina
Prior art keywords
hcc
oxo
treatment
hepatocellular carcinoma
piridazine
Prior art date
Application number
ARP130103990A
Other languages
English (en)
Inventor
Dr Bladt Friedhelm
Dr Friese-Hamim Manja
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of AR093318A1 publication Critical patent/AR093318A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo o una de sus sales y/o solvatos farmacéuticamente aceptables para usar para el tratamiento de carcinoma hepatocelular (HCC). Reivindicación 2: Clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo hidratado para usar para el tratamiento de carcinoma hepatocelular (HCC).
ARP130103990A 2012-11-02 2013-11-01 Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc) AR093318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12007494 2012-11-02

Publications (1)

Publication Number Publication Date
AR093318A1 true AR093318A1 (es) 2015-05-27

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103990A AR093318A1 (es) 2012-11-02 2013-11-01 Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc)

Country Status (26)

Country Link
US (1) US20150283137A1 (es)
EP (1) EP2914264B1 (es)
JP (1) JP6255028B2 (es)
KR (1) KR102131588B1 (es)
CN (1) CN104768553A (es)
AR (1) AR093318A1 (es)
AU (1) AU2013339823B2 (es)
BR (1) BR112015008279A2 (es)
CA (1) CA2890273C (es)
DK (1) DK2914264T3 (es)
ES (1) ES2646913T3 (es)
HK (1) HK1211869A1 (es)
HR (1) HRP20171295T1 (es)
HU (1) HUE035483T2 (es)
IL (1) IL238536B (es)
LT (1) LT2914264T (es)
MX (1) MX354518B (es)
NO (1) NO2914264T3 (es)
PL (1) PL2914264T3 (es)
PT (1) PT2914264T (es)
RS (1) RS56485B1 (es)
RU (1) RU2650679C2 (es)
SG (1) SG11201503214YA (es)
SI (1) SI2914264T1 (es)
WO (1) WO2014067610A1 (es)
ZA (1) ZA201503924B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2665932C2 (ru) 2013-08-14 2018-09-05 Югэнкайся Дзяпан Цусё Гидропонная система культивирования и завод для выращивания растений, включающий гидропонную систему культивирования и пенополистироловую теплицу
MX2022000358A (es) * 2019-07-10 2022-02-03 Merck Patent Gmbh Preparacion farmaceutica.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
EP2373640B1 (en) * 2009-01-08 2014-07-30 Merck Patent GmbH Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
EP2914264B1 (en) 2017-08-09
ZA201503924B (en) 2020-11-25
AU2013339823B2 (en) 2018-01-04
US20150283137A1 (en) 2015-10-08
LT2914264T (lt) 2017-11-10
PL2914264T3 (pl) 2017-12-29
KR102131588B1 (ko) 2020-07-08
RS56485B1 (sr) 2018-01-31
MX354518B (es) 2018-03-08
CA2890273C (en) 2021-10-26
CA2890273A1 (en) 2014-05-08
CN104768553A (zh) 2015-07-08
RU2015120692A (ru) 2016-12-27
IL238536A0 (en) 2015-06-30
EP2914264A1 (en) 2015-09-09
BR112015008279A2 (pt) 2017-07-04
AU2013339823A1 (en) 2015-06-18
SG11201503214YA (en) 2015-05-28
RU2650679C2 (ru) 2018-04-17
HUE035483T2 (hu) 2018-05-02
MX2015005265A (es) 2015-07-17
NO2914264T3 (es) 2018-01-06
PT2914264T (pt) 2017-11-14
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
HRP20171295T1 (hr) 2017-10-20
WO2014067610A1 (en) 2014-05-08
DK2914264T3 (en) 2017-09-11
JP6255028B2 (ja) 2017-12-27
HK1211869A1 (en) 2016-06-03
ES2646913T3 (es) 2017-12-18
JP2015536957A (ja) 2015-12-24
IL238536B (en) 2019-01-31

Similar Documents

Publication Publication Date Title
HUE046008T2 (hu) I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
EA201390275A1 (ru) Кристаллический (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпиридин-4-ил)этокси)-1h-индазол-3-ил)винил)-1h-пиразол-1-ил)этанол
DK2373640T3 (da) Hidtil ukendte polymorfe former af 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitril-hydrochloridsalt og fremgangsmåder til fremstilling deraf
HRP20182059T1 (hr) Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja
MX2016012687A (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
PH12019500252A1 (en) Compound for use in the treatment of neurogenic orthostatic hypotension
AR093318A1 (es) Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc)
CL2017001478A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr)
BR112015010121A2 (pt) inibidores de quinase de tirosina de bruton
PH12017500719A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
IL268128A (en) n1-(4-(5-(cyclopropylmethyl)-1-methyl-1-h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or Iraki inhibitors for cancer therapy
MX343273B (es) Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma.
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
AR092991A1 (es) Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek)
AR099035A1 (es) Derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento de carcinoma de células renales (rcc)
UY34194A (es) ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
UY32493A (es) " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones"
IT201700035938A1 (it) Bocca di erogazione per bancomat, atm o accettatori di banconote
CN302029109S (zh) 门禁刷卡机(三合一)
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность

Legal Events

Date Code Title Description
FC Refusal